However, the MMRM least squares mean (LSM) ADCS-iADL change from baseline at week 104 showed a nominally significant increase in clinical decline rate of the 5,600 mg arm compared with placebo.
← all excerpts
Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
1
—
—